Provided by Tiger Trade Technology Pte. Ltd.

Celldex Therapeutics

31.65
-0.5300-1.65%
Post-market: 32.000.3500+1.11%19:38 EDT
Volume:2.41M
Turnover:76.17M
Market Cap:2.48B
PE:-7.29
High:32.54
Open:32.26
Low:30.98
Close:32.18
52wk High:45.14
52wk Low:22.10
Shares:78.49M
Float Shares:73.02M
Volume Ratio:1.22
T/O Rate:3.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3401
EPS(LYR):-3.9000
ROE:-43.88%
ROA:-27.62%
PB:3.48
PE(LYR):-8.12

Loading ...

Celldex Therapeutics Says Barzolvolimab Meets Primary Efficacy Endpoint In Phase 2 CSU Study

Reuters
·
Jun 14

Celldex says Phase 2 barzolvolimab data show sustained off-treatment angioedema improvement in CSU patients

Reuters
·
Jun 14

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained off-Treatment Improvement in Angioedema in Patients With Csu at the European Academy of Allergy and Clinical Immunology Annual Meeting

THOMSON REUTERS
·
Jun 14

Celldex Therapeutics - Barzolvolimab Meets Primary Efficacy Endpoint in Phase 2 Csu Study

THOMSON REUTERS
·
Jun 14

Celldex reports positive Phase 1 results for bispecific antibody CDX-622 in healthy participants

Reuters
·
Jun 14

Celldex Presents Positive First-in-Human Results From Phase 1 Study of Novel Bispecific Cdx-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

THOMSON REUTERS
·
Jun 14

Celldex to present barzolvolimab, CDX-622 data at EAACI annual congress

Reuters
·
Jun 11

Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress

GlobeNewswire
·
Jun 11

Celldex Therapeutics Is Maintained at Buy by UBS

Dow Jones
·
Jun 11

UBS Adjusts Price Target on Celldex Therapeutics to $45 From $38, Maintains Buy Rating

MT Newswires Live
·
Jun 10

Celldex price target raised to $45 from $38 at UBS

TIPRANKS
·
Jun 10

U.S. RESEARCH ROUNDUP- Datadog, Eli Lilly, Oracle

Reuters
·
Jun 10

A Look At Celldex Therapeutics (CLDX) Valuation After Recent Share Price Pullback And Mixed P/B And DCF Signals

Simply Wall St.
·
Jun 10

Celldex publishes investor presentation highlighting barzolvolimab late-stage urticaria trials and broader mast cell disease pipeline

Reuters
·
May 28

Celldex Therapeutics Is Maintained at Overweight by Wells Fargo

Dow Jones
·
May 13

U.S. RESEARCH ROUNDUP-Aecom, Humana, Mosaic

Reuters
·
May 13

The Bull Case For Celldex Therapeutics (CLDX) Could Change Following Q1 Loss And Barzolvolimab Milestones

Simply Wall St.
·
May 12

Celldex Therapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
May 08

Celldex Therapeutics Inc expected to post a loss of $1.15 a share - Earnings Preview

Reuters
·
May 08

Celldex price target raised to $48 from $45 at Barclays

TIPRANKS
·
May 08